Form 4 for STOK Stoke Therapeutics, Inc.

Accepted 2026-03-19 00:00:00 ET · period of report 2026-03-17 · accession 0001774690-26-000006 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2026-03-19	2026-03-17+	STOK	Leggett Thomas	CFO	S - Sale	$32.14	-4,578	13.5K	-25%	-$147.1K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-03-17	S	D	922	$33.38	12,554	D	—	—	(F3) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive.
2	Common	Common Stock	2026-03-18	S	D	37	$32.85	10,172	D	—	—
3	Common	Common Stock	2026-03-18	S	D	172	$31.79	10,209	D	—	—	(F5) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive.
4	Common	Common Stock	2026-03-18	S	D	2,173	$31.28	10,381	D	—	—	(F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive.
5	Common	Common Stock	2026-03-17	S	D	1,274	$32.74	13,476	D	—	—	(F2) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.